George Vasquez-Rios, MD, explains how the ASN's GD-C Compendium curates glomerular disease guidance for general clinicians and specialists alike.
|Articles|May 31, 2007
Internal Medicine World Report
- May 2007
- Volume 0
- Issue 0
Top Retail Health Clinics in the United States
Advertisement
Articles in this issue
over 19 years ago
Bacterial Meningococcal Disease Alert: The Case for Vaccinationover 19 years ago
First Once-Daily Oral Therapy Promising Option for Relapsing MSover 19 years ago
End of an Era: Garlic Has No Effect on LDL Cholesterolover 19 years ago
Vitamin K May Reverse Warfarin-Induced Arterial Calcificationover 19 years ago
Why Insomnia Is Bad for Your HealthAdvertisement
Related to this article
Andrew Cutler, MD, says real-world MDD patients respond to adjunctive cariprazine like trial participants, with gains in mood and function within weeks.
Frances Lee, MD, on the stigma driving under-detection of ALD and its disproportionate rise in women and younger adults.
SOCS leaders explain SOCS Serves, a toolkit-based program connecting dermatology volunteers with students and underserved communities.
EMBARQ-CSU1 and EMBARQ-CSU2 showed sustained reductions in urticaria, with the antibody meeting all primary and key secondary endpoints at Week 12.
The FDA-approved update adds phase 3 HYPERION data on adults diagnosed with PAH within the past year.
Josh Woolley, MD, PhD, explains why current active placebos fail to mask high-dose psilocybin trials and outlines a framework proposed to fix it.
Raj Chovatiya, MD, PhD, on zasocitinib results in the scalp, nails, palms and soles, speed of response and once-daily oral dosing in psoriasis.
Advertisement
Advertisement
Trending on HCPLive
1
Half-Life vs. Real Life: How Real-World Evidence Is Reframing Wet AMD Treatment
2
FAQ: What the Expanded Marstacimab Approval Means for Hemophilia A, B
3
FDA Updates Sotatercept Label with HYPERION Data in Early PAH
4
Q&A: Zasocitinib Response in the Scalp, Nails, Palms and Soles
5